Palovarotene is primarily used in the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes abnormal bone formation in muscles, tendons, and ligaments. It works as a selective agonist of the retinoic acid receptor gamma (RARγ), which plays a key role in the signaling pathways that regulate bone formation. By activating RARγ, it helps to reduce the formation of new bone in soft tissues, slowing the progression of the disease and improving patient quality of life. Additionally, it is being investigated for its potential in treating other conditions involving abnormal bone formation, such as heterotopic ossification. Its targeted mechanism offers a promising therapeutic approach for these challenging disorders.